Rigel Pharmaceuticals, Inc.
DE ˙ DB ˙ US7665596034
SecurityDE:RI2 / Rigel Pharmaceuticals, Inc.
InstitutionRhumbline Advisers
Latest Disclosed Ownership22,692 shares
Latest Disclosed Value $ 613,582
Rhumbline Advisers reports 1.13% decrease in ownership of RI2 / Rigel Pharmaceuticals, Inc.

On May 12, 2026 - Rhumbline Advisers filed a 13F-HR form disclosing ownership of 22,692 shares of Rigel Pharmaceuticals, Inc. (DE:RI2) valued at $613,582 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 22,952 shares of Rigel Pharmaceuticals, Inc.. This represents a change in shares of -1.13% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 22,692 -260 -1.13 614 -37.64 0.0005
2026-02-13 2025-12-31 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 22,952 -3,453 -13.08 983 31.42 0.0008
2025-11-06 2025-09-30 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 26,405 -660 -2.44 748 47.83 0.0006
2025-08-12 2025-06-30 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 27,065 555 2.09 507 6.30 0.0004
2025-05-29 2025-03-31 13F/A-1 RIGEL PHARMACEUTICALS INC COM COM 766559702 26,510 1,367 5.44 477 12.80 0.0004
2025-04-08 2025-03-31 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 26,510 1,367 477 0.0004
2025-05-29 2024-12-31 13F/A-1 RIGEL PHARMACEUTICALS INC COM COM 766559702 25,143 1,485 6.28 423 10.47 0.0004
2025-01-30 2024-12-31 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 25,143 1,485 423 0.0004
2024-11-12 2024-09-30 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 23,658 -1,342 -5.37 383 86.34 0.0003
2024-08-01 2024-06-30 13F RIGEL PHARMACEUTICALS INC COM COM 766559702 25,000 25,000 205 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.